About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Key TakeawaysVertex shares slipped in extended trading Wednesday after the company announced it had agreed to acquire Alpine Immune Sciences for $4.9 billion.The deal values each Alpine share at $65, representing a 38% premium to Wednesday’s closing price of $47.04.The acquisition provides Vertex with access to Alpine’s mid-stage development antagonist povetacicept to treat a kidney autoimmune disease called IgA nephropathy (IgAN).The Vertex share price may find buying interest around $390 from an uptrend l ...

Alpine Immune Sciences CEO Mitchell Gold in 2017. (AIS Photo)Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s closing price on Wednesday afternoon.The premium would have been higher, around 67%, based on Alpine’s closing price on Tuesday. However, the company’s stock jumped 21% in regular trading Wednesday after Bloomberg News reported it was considering a sale.Alpine ...

Vertex Pharmaceuticals (VRTX) will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences (ALPN), the companies said late Wednesday. Alpine stock rocketed almost 21% on rumors of the deal.X Alpine's lead product is in development for patients with IgA nephropathy, a chronic kidney disease that progresses over 10 to 20 years, and can lead to end-stage renal disease, according to Johns Hopkins researchers. The company is due to begin a Phase 3 study in the second half of this year.Th ...

Alpine Immune Sciences, Inc. (ALPN) shares ended the last trading session 10.4% higher at $38.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks.The sudden increase in the stock can be attributed to the rising optimism around the company's progress with its pipeline candidates, povetacicept and acazicolcept, which are being developed for treating various autoimmune and inflammato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37449 Registrant's telephone number, including area code: (206) 788-4545 Securities registered pursuant to Section 12(b) of the Act: | --- | --- ...

Alpine Immune Sciences, Inc. (ALPN) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.32 per share. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 146.88%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.24, delivering a surprise of 31.43%.Over the last four quarte ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Results Conference Call March 18, 2024 4:30 PM ET Company Participants Temre Johnson - Senior Director, Investor Relations and Corporate Communications Mitchell Gold - Executive Chairman and Chief Executive Officer Stanford Peng - President and Head of Research & Development Paul Rickey - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Mike Ulz - Morgan Stanley Thomas Smith - Leerink Partners Matt Biegler - Oppenheimer Joe Pant ...

Exhibit 99.1 Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results -- Clinical data on povetacicept in IgA nephropathy will be updated at the upcoming WCN meeting, including follow up at 80 mg and initial data at 240 mg SC once every four-weeks -- -- Povetacicept advancing towards a pivotal phase 3 trial in IgA nephropathy and a phase 2 trial in systemic lupus erythematosus -- SEATTLE, Washington - March 18, 2024 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinic ...

Investors are always looking for stocks that are poised to beat at earnings season and Alpine Immune Sciences, Inc. (ALPN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Alpine Immune Sciences is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possi ...